Maxim Group reiterated their buy rating on shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) in a research note issued to investors on Wednesday morning. Maxim Group currently has a $5.00 price target on the biotechnology company’s stock.

Several other research analysts also recently issued reports on VKTX. ValuEngine upgraded shares of Viking Therapeutics from a strong sell rating to a sell rating in a report on Thursday, September 7th. HC Wainwright reiterated a buy rating and set a $7.00 price target (up from $5.00) on shares of Viking Therapeutics in a report on Monday, July 17th.

Shares of Viking Therapeutics (NASDAQ VKTX) opened at 2.08 on Wednesday. The firm’s market capitalization is $57.61 million. The stock has a 50 day moving average price of $1.50 and a 200 day moving average price of $1.50. Viking Therapeutics has a 1-year low of $0.90 and a 1-year high of $2.16.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Equities research analysts anticipate that Viking Therapeutics will post ($0.82) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Viking Therapeutics’ (VKTX) Buy Rating Reiterated at Maxim Group” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/07/viking-therapeutics-vktx-buy-rating-reiterated-at-maxim-group.html.

Several large investors have recently made changes to their positions in the company. Sabby Management LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth $525,000. Renaissance Technologies LLC increased its holdings in shares of Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after buying an additional 102,600 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Viking Therapeutics during the second quarter worth $124,000. Institutional investors own 5.67% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Stock Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related stocks with our FREE daily email newsletter.